Therefore, it has been suggested that CRP serum levels and, by extension, disease activity scores containing this APR are not sensitive markers of inflammation (synovitis) in patients treated with anti-IL-6R or JAKi, in contrast to other biological therapies, such as TNF inhibitors. This evidence concerns the gene IL6R and synovitis.